权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Characterization of enzymes in the vitamin K cycle

维生素 K 循环中酶的表征

基本信息

批准号：
9281897
负责人：
DARREL W STAFFORD
金额：
$ 47.93万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-01 至 2020-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9281897
关键词：
Active Sites Affect Alpha Cell Anticoagulants Back Biological Assay Biological Process Blood Coagulation Disorders Blood coagulation Cell Line Cell surface Cells Clinical Clustered Regularly Interspaced Short Palindromic Repeats Coagulation Factor Deficiency Complex Cysteine Data Disease Enzymes Epoxy Compounds Fluorescence-Activated Cell Sorting Funding Generations Genes Goals Hemostatic function Hereditary Disease Human Individual Knock-out Knowledge Lead Libraries Link Mediating Missense Mutation Molecular Monitor Mutation Natural regeneration Oxides Pathway interactions Patients Physiological Physiological Processes Post-Translational Protein Processing Production Proteins Pseudoxanthoma Elasticum Reducing Agents Reporter Reporting Resistance Role Signal Transduction Single Nucleotide Polymorphism Structure Structure-Activity Relationship Syndrome Testing Thrombosis Variant Vascular calcification Vitamin K Vitamin K Reductase Warfarin base bone metabolism carboxylate carboxylation cardiovascular risk factor clinical phenotype cofactor design dosage enzyme mechanism extracellular fluindione gamma-glutamyl carboxylase genome-wide improved in vivo insight knockout gene loss of function matrix Gla protein mutant novel therapeutics paralogous gene protein function public health relevance reduced vitamin K screening tool vitamin K epoxide reductase vitamin K1 oxide vitamin therapy

项目摘要

DESCRIPTION (provided by applicant): Vitamin K-dependent (VKD) carboxylation, an essential post-translational modification catalyzed by gamma-glutamyl carboxylase (GGCX), is required for the biological functioning of proteins that control blood coagulation, vascular calcification, bone metabolism, and other important physiological processes. Concomitant with carboxylation, reduced vitamin K (KH2) is oxidized to vitamin K epoxide (KO). Since humans cannot synthesize vitamin K, KO must be converted back into KH2 in a two-step reduction to complete the vitamin K cycle; this reduction is accomplished by the enzyme vitamin K epoxide reductase (VKOR) and, as we hypothesize, vitamin K reductase (VKR). Despite significant progress in understanding of the enzymes in the vitamin K cycle, fundamental questions remain: 1) Why do some mutations of GGCX result in the bleeding disorder referred to as combined vitamin K-dependent coagulation factors deficiency (VKCFD), while others are linked with Pseudoxanthoma elasticum (PXE)-like syndrome? 2) What are the identities of the VKR enzymes? 3) What is the mechanism for VKOR active site regeneration? 4) Does VKORC1L1, the paralogous enzyme of VKOR, contribute to the vitamin K cycle under physiological conditions? The current proposal aims to identify and characterize the unknown components of the vitamin K cycle, to understand how these various components contribute to VKD carboxylation in the cellular milieu, and to determine how naturally-occurring GGCX mutations contribute to different disease states. To accomplish these goals, we propose the following specific aims. Aim 1: To study GGCX function using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 mediated GGCX knockout cells, in order to understand how GGCX mutations are related to VKCFD and PXE-like syndromes. Aim 2: To characterize and identify VKR using genome-scale CRISPR-Cas9 knockout loss-of-function screening in our HEK293 reporter cell line. Aim 3: To characterize VKOR, naturally-occurring VKOR mutants, and VKORC1L1 in our double-gene knockout HEK293 reporter cells. Information derived from these studies will help us understand how the various vitamin K cycle components contribute to these complex mechanisms, thereby gaining new therapeutic insights into the control of thrombosis and improving therapies for vitamin K-related disorders.